Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faster Elimination of HPV in Rwanda
NCT06536855Phase 4Not yet recruiting
- Sponsor
- Rwanda Biomedical Centre
- Start
- Sep 2024
- Primary completion
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), sponsored by Rwanda Biomedical Centre. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on NCT06536855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536855.